biotech » Trang Công Nghệ | Trangcongnghe.vn

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Globe Newswire

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Globenewswire -

Hummingbird Bioscience Appoints Dr. James Garner as President

Globe Newswire

Hummingbird Bioscience Appoints Dr. James Garner as President

Globenewswire -

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Globe Newswire

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

Globenewswire -

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Globe Newswire

Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer

Globenewswire -

Sarat Ventures Y Innovations Biotech Fund to Invest in Early-Stage Companies with a focus in Saudi Arabia and the MENA Region

Globe Newswire

Sarat Ventures Y Innovations Biotech Fund to Invest in Early-Stage Companies with a focus in Saudi Arabia and the MENA Region

Globenewswire -

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer

Globe Newswire

Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer

Globenewswire -

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Globe Newswire

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Globenewswire -

XEM THÊM TIN MỚI